ARCHIVES

Final Results from CLEOPATRA Phase III Trial Show Perjeta Increased OS 15.7 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

$14.7 Million Earmark Of NCI funds Trigger Protest By Advocates, Scientists

October 24, 1996

Obituary: Patricia Delaney, FDA Cancer Liaison.

June 6, 2008

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

January 17, 1992

“Confidential and Proprietary” Document Proposes Plan for National Network

February 7, 2014

Advisors OK Planning Grants In Breast Cancer For Cancer Centers

July 9, 1993

NCCN, McKesson Form Partnership To Build Clinical Support Software

November 30, 2012